Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Syncona (SYNC)

Price 127.00p on 26-04-2024 at 03:45:13
Change 1.00p 0.79%
Buy 127.00p
Sell 125.60p
Buy / Sell SYNC Shares
Last Trade: Unknown 2.00 at 127.113p
Day's Volume: 217,073
Last Close: 127.00p
Open: 124.00p
ISIN: GG00B8P59C08
Day's Range 124.00p - 127.20p
52wk Range: 105.00p - 162.20p
Market Capitalisation: £830m
VWAP: 125.9066p
Shares in Issue: 653m

Recent Trades History Syncona (SYNC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 2 127.113p OTC Trade
16:55:53 - 25-Apr-24
Unknown* 1 127.013p OTC Trade
16:55:53 - 25-Apr-24
Unknown* 923 127.00p OTC Trade
16:55:14 - 25-Apr-24
Unknown* 5,500 125.055p OTC Trade
16:40:56 - 25-Apr-24
Unknown* 9,078 127.00p OTC Trade
16:17:13 - 25-Apr-24
Unknown* 1,268 127.006p OTC Trade
15:56:15 - 25-Apr-24
Buy* 17,081 127.00p Ordinary
15:35:45 - 25-Apr-24
Buy* 37,183 127.00p Suspected BUY Trade
15:35:26 - 25-Apr-24
Sell* 2,303 127.00p Automatic Execution
15:25:51 - 25-Apr-24
Buy* 1,273 127.20p Automatic Execution
15:14:40 - 25-Apr-24

Share Price History for Syncona

Time period:
to
Date Open High Low Close Volume

Share News for Syncona

Syncona agrees to sell stake in investee company for GBP7.4 million

11th Apr 2024 14:22

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc. Read More

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

4th Apr 2024 17:06

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles. Read More

Syncona portfolio company Autolus posts widened loss for 2023

14th Mar 2024 14:16

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses. Read More

IN BRIEF: Freeline shareholders approve Syncona acquisition

12th Feb 2024 18:01

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona. Read More

UPDATE: Syncona portfolio strengthens thanks to Autolus

8th Feb 2024 13:45

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes. Read More

FTSE 100 Latest
Value8,078.86
Change38.48

Login to your account

Forgot Password?

Not Registered